Aufrufe: 70
Audio
Teilen
Regulatory News:
Vetoquinol (Paris:VETO):
Sales for the third quarter of 2026 totaled €140 million, up +10.4% compared to the prior year on a reported basis and +9.6% at constant exchange rates, driven by a favorable currency impact of €1 million from the U.S. and the Americas excluding the U.S.
The company’s business was driven by the Essentials segment, which grew by +13.9% on a reported basis and +12.9% at constant exchange rates.
Business was solid in most regions. At constant exchange rates, it grew by 8% in Europe, 11% in the United States, and 23% in the Asia-Pacific/Rest of the World region; it declined by 1% in the Americas excluding the U.S.
These results take into account a -€0.6 million impact from the simplification of complementary product lines during the quarter, in line with the normalization of the simplification program.
This third quarter continues the growth momentum observed during the first half of the fiscal year; it benefited in particular from a favorable base effect from the third quarter of 2025.
For the first nine months of the fiscal year, the company’s sales grew by +3.9% on a reported basis to €399M and by +5.4% on a constant-currency basis, after accounting for a -€3.7 million impact from the simplification of complementary product lines since the beginning of the year (-€7.7 million as of the end of September 2025) as well as a negative currency effect of -€6.1 million.
On a constant-currency basis and excluding the product line simplification, sales at the end of September 2026 were up 6.6% year-to-date.
Over this period, the Essentials segment grew by +6.0% on a reported basis and by +6.7% on a constant-currency basis. As of the end of September 2026, it accounted for 64.9% of the company’s sales (vs. 63.6% as of the end of September 2025).
On a constant-currency basis, Europe grew by +4.6%, the U.S. by +12.4%, Asia-Pacific/Rest of the World by +4.6%, and the Americas excluding the U.S. declined slightly by -0.9%.
Next release: 2026 annual sales, January 14, 2027 (after market close).
Group Sales Trends – September 2025–September 2026
ABOUT VETOQUINOL
Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.
Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats).
Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. As of June 30, 2026, Vetoquinol employed 2,526 people.
Vetoquinol has been listed on Euronext Paris since 2006 (ticker symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
APPENDICES
Quaterly sales
| €m | 2026 | 2025 | Change (reported basis) | Change at (constant exchange rates) |
| Q1 Sales | 125.0 | 130.6 | -4.3% | -0.3% |
| Q2 Sales | 134.3 | 127.0 | +5.7% | +7.2% |
| Q3 Sales | 139.7 | 126.6 | +10.4% | +9.6% |
| YTD Sep. sales | 399.0 | 384.2 | +3.9% | +5.4% |
Sales by strategic territory
| €m | September 30, 2026 | September 30, 2025 | Change (reported basis) | Change at (constant exchange rates) |
| Europe | 197.8 | 189.6 | +4.4% | +4.6% |
| Americas excluding the U.S.A. | 53.7 | 53.6 | +0.3% | -0.9% |
| U.S.A. | 86.9 | 80.3 | +8.2% | +12.4% |
| Asia-Pacific / Rest of the World | 60.6 | 60.7 | -0.2% | +4.6% |
| YTD Sep. sales | 399.0 | 384.2 | +3.9% | +5.4% |
ALTERNATIVE PERFORMANCE INDICATORS
Vetoquinol Group management believes that these indicators, which are not defined by IFRS, provide additional information that is relevant to shareholders in their analysis of the Group's underlying trends, performance and financial position. These indicators are used by management to analyze performance.
Essentials products: The products referred to as “Essentials” comprise veterinary drugs and non-medical products sold by the Vetoquinol Group. They are existing or potential market-leading products designed to meet the daily requirements of vets in the companion animal or farm animal sector. They are intended for sale worldwide and their scale effect improves their economic performance.
Constant exchange rates: Application of the previous period’s exchange rates to the current financial year, all other things remaining equal.
Organic growth: Organic growth refers to growth in Vetoquinol's sales due to an increase in sales volume and/or prices in year N compared with year N-1, at constant exchange rates and scope of consolidation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261028668186/en/
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
